- Meeting abstract
- Open Access
Allergen specific sublingual immunotherapy (ASSIT) reduces Il-4 and enhances interferon-gamma intracellular expression by Cd8+ T-cells in perenneal allergic rhinitis (Par)
© Farag – Mahmod et al; licensee BioMed Central Ltd. 2012
- Published: 2 November 2012
- Clinical Response
- Symptom Score
- Allergic Rhinitis
- Allergic Disease
ASSIT is a novel therapy of allergic diseases that gained significant acceptance over the past decade. This study was undertaken to investigate whether ASSIT in PAR may influence the Intracellular expression of IFN- gamma and IL-4 by CD3+CD8+ T-cells.
Twenty adult PAR patients sensitive only to the mite D.farinae as diagnosed by Prick skin testing (PST) [Omega labs, Montreal, Canada] were included in the study. ASSIT to D. farinae was administered for 6 months.
Flow cytometric evaluation of the intracellular expression of IL-4 and IFN- gamma by CD3+ CD8+ T-cells was determined according to Manufacturer instructions (Beckton Dickenson) before and after ASSIT.
The total 5 symptom score (T5SS) of PAR and the diameter of PST were also examined.
After ASSIT; the percentage of Il-4 expressing CD8+ T-cells significantly decreased from [0.69 +/- 0.18] to [0.33 +/- 0.13] and the percentage of IFN-gamma expressing CD8+ T-cells significantly increased from [4.63 +/- 1.29] to [7.20 +/- 2.09]. The T5SS and the PST diameter also significantly decreased.
In this study the favorable clinical response induced by ASSIT in PAR correlated with the decrease in the percentage of Tc2 cells and the increase in the percentage of Tc1 cells.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.